GSE182150 KIT LSD1 MYC inhibition 2 v 7 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182150_KIT_LSD1_MYC inhibition_2_v_7_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182150_KIT_LSD1_MYC inhibition_2_v_7_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182150_KIT_LSD1_MYC inhibition_2_v_7_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182150_KIT_LSD1_MYC inhibition_2_v_7_human_up.

Results found

Linked to

 

Label

Description

 

Gene

MSL complex subunit 3B

Gene

Gfo/Idh/MocA-like oxidoreductase domain containing 3, pseudogene

Gene

AMZ2 pseudogene 1

Gene

ZNF667 antisense RNA 1

Gene

RASSF8 antisense RNA 1

Gene

PSMA3 antisense RNA 1

Gene

long intergenic non-protein coding RNA 3057

Gene

ATP2B1 antisense RNA 1

Gene

CLN8 antisense RNA 1

Gene

long intergenic non-protein coding RNA 865

  • Gene

    MSL complex subunit 3B


  • Gene

    Gfo/Idh/MocA-like oxidoreductase domain containing 3, pseudogene


  • Gene

    AMZ2 pseudogene 1


  • Gene

    ZNF667 antisense RNA 1


  • Gene

    RASSF8 antisense RNA 1


  • Gene

    PSMA3 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 3057


  • Gene

    ATP2B1 antisense RNA 1


  • Gene

    CLN8 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 865

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.